key: cord-0740405-j5oilen3 authors: Fitzgerald, Kathryn C; Mecoli, Christopher A; Douglas, Morgan; Harris, Samantha; Aravidis, Berna; Albayda, Jemima; Sotirchos, Elias S; Hoke, Ahmet; Orbai, Ana-Maria; Petri, Michelle; Christopher-Stine, Lisa; Baer, Alan N; Paik, Julie J; Adler, Brittany L; Tiniakou, Eleni; Timlin, Homa; Bhargava, Pavan; Newsome, Scott D; Venkatesan, Arun; Chaudhry, Vinay; Lloyd, Thomas E; Pardo, Carlos A; Stern, Barney J; Lazarev, Mark; Truta, Brindusa; Saidha, Shiv; Chen, Edward S; Sharp, Michelle; Gilotra, Nisha; Kasper, Edward K; Gelber, Allan C; Bingham, Clifton O; Shah, Ami A; Mowry, Ellen M title: Risk Factors For Infection And Health Impacts Of The Covid-19 Pandemic In People With Autoimmune Diseases date: 2021-05-06 journal: Clin Infect Dis DOI: 10.1093/cid/ciab407 sha: f914cf3d0fda721df7ab2347f02affacda5d5a07 doc_id: 740405 cord_uid: j5oilen3 BACKGROUND: People with autoimmune or inflammatory conditions taking immunomodulatory/suppressive medications may have higher risk of novel coronavirus disease 2019 (COVID-19). Chronic disease care has also changed for many patients, with uncertain downstream consequences. METHODS: We included participants with autoimmune or inflammatory conditions followed by specialists at Johns Hopkins. Participants completed periodic surveys querying comorbidities, disease-modifying medications, exposures, COVID-19 testing and outcomes, social behaviors, and disruptions to healthcare. We assessed whether COVID-19 risk is higher among those on immunomodulating or suppressive agents and characterized pandemic-associated changes to care and mental health. RESULTS: 265 (5.6%) developed COVID-19 over 9 months of follow-up (April-December 2020). Patient characteristics (age, race, comorbidity, medications) were associated with differences in social distancing behaviors during the pandemic. Glucocorticoid exposure was associated with higher odds of COVID-19 in models incorporating behavior and other potential confounders (OR: 1.43; 95%CI: 1.08, 1.89). Other medication classes were not associated with COVID-19 risk. Diabetes (OR: 1.72; 95%CI: 1.08, 2.73), cardiovascular disease (OR: 1.68; 95%CI: 1.24, 2.28), and kidney disease (OR: 1.76; 95%CI: 1.04, 2.97) were associated with higher odds of COVID-19. Of the 2156 reporting pre-pandemic utilization of infusion, mental health or rehabilitative services, 975 (45.2%) reported disruptions therein, which disproportionately affected individuals experiencing changes to employment or income. CONCLUSIONS: Glucocorticoid exposure may increase risk of COVID-19 in people with autoimmune or inflammatory conditions. Disruption to healthcare and related services was common. Those with pandemic-related reduced income may be most vulnerable to care disruptions. In people with autoimmune or inflammatory conditions, there is concern that immunomodulatory medications used to treat these conditions may increase the risk of developing novel coronavirus disease 2019 (COVID-19) based on their mechanisms of action and data from earlier studies. [1] [2] [3] [4] [5] [6] [7] Most existing COVID-19 studies failed to account for social distancing behaviors. Such behavior differences may confound (or impact in unexpected ways) estimates of medication-associated risks (e.g., individuals taking stronger immune-modulating/suppressive medications may perceive higher COVID-19 risk and thus more strictly practice social distancing or refrain from in-person socialization). Controlling for behavior is a critical component in analyses assessing COVID-19 risk associated with exposure to immunomodulatory/suppressive medications. Beyond COVID-19 risk concerns, the pandemic has altered care in many chronic conditions. For example, many patients have discontinued, lowered, or delayed their medication or refrained from obtaining critical safety laboratory tests. [8, 9] Others experienced disruptions to infusion, rehabilitative, homecare, or mental health services. Currently, limited research has assessed 1) which patients are most vulnerable to care disruption and 2) the downstream effects of these disruptions on disease outcomes. The impact of such changes may be very significant, as they may affect the majority of patients with autoimmune or inflammatory conditions, not only those who develop COVID-19. We sought to assess whether risk for COVID-19 is higher among those on immunomodulating or suppressive agents (after accounting for behavior) and to quantify and identify consequences of pandemic-associated changes to longitudinal outpatient care and mental health in this population. To do so, we established COVID-19 Risk with Immune-modulating Medication Study (COVID-RIMS), a cohort study of nearly 5000 individuals with a variety of autoimmune and inflammatory conditions A c c e p t e d M a n u s c r i p t managed as outpatients by specialists at the Johns Hopkins Medical Institutions. We established the COVID-RIMS study in April 2020. Eligible participants had autoimmune or inflammatory conditions (included diagnoses listed in Supplemental Table 1 ) and had been seen by relevant specialists at Johns Hopkins within the past 3 years. Participants had at least two ICD-10 codes associated with a particular disorder in the electronic medical record at two separate visits prior to study initiation. Patients were invited to participate in COVID-RIMS through an individualized e-mail link. From April through June 2020, COVID-RIMS participants answered weekly online questionnaires, and from July 2020 onwards, they completed surveys on an approximately monthly basis. Surveys queried COVID-19 testing and results, participant characteristics (including demographic, medication and comorbidity), behaviors, mental health, and pandemic-associated changes to healthcare; a more detailed description is provided in the Supplemental Methods. In each survey, participants were asked several COVID-19-related questions including whether 1) a health provider ever suspected them of having COVID-19, 2) they had tested positive for COVID-19, or 3) had received a positive COVID-19 serology assessment. In addition, Johns Hopkins also maintains a COVID-19 registry in which all tests, results and COVID-19 outcomes performed within the state of Maryland or District of Columbia (via the Chesapeake Regional Information System for our Patients [CRISP], a health information exchange resource for Maryland/District of Columbia) are automatically uploaded into a database designed for research; we linked participants in COVID-RIMS A c c e p t e d M a n u s c r i p t with this registry to allow for maximum case capture. Participants with self-reported positive COVID-19 tests or serum antibody testing, self-reported healthcare provider suspected COVID-19 (but were never tested), and those who had tested positive in CRISP were included as cases. We performed sensitivity analyses excluding individuals with suspected COVID-19 from the case definition. Initial analyses compared demographic characteristics of invited participants versus those who agreed to participate. We evaluated non-medication associated risk factors for COVID-19 (see Supplemental Methods) using logistic regression, as exact timing of infection was not always clear. Primary analyses assessed the association between exposure to immunomodulatory agent classes and odds of COVID-19 using multivariable-adjusted logistic regression models. A full list of individual medications considered, and their associated class, are included in the Supplementary Methods. We also assessed COVID-19 risk associated with medication classes stratified by disorders and individual medication exposures for medication classes or medications in which at least 10 COVID-19 cases were recorded. We then evaluated predictors of interruptions to care using logistic regression models. Lastly, we assessed how depression and anxiety symptoms changed longitudinally and evaluated predictors of higher overall symptom burden using mixed effects models. Statistical calculations were performed with R software, version 3.6.2. [10] Of the invited 22,516 eligible patients, 4666 (20.9%) agreed to participate and completed at least one follow-up survey as of December 2020. Multiple sclerosis (MS), Sjogren's syndrome, and rheumatoid arthritis were the most common qualifying conditions represented, with 878, 741, and 545 individuals, respectively (Supplemental Table 1 ). COVID-RIMS participants were more likely to be female (76.7% vs. 72.3%), white (83.1% vs. 63.2%) and have higher SES (mean ADI [SD] 23.7 [20.4] vs. 31.2 [24.4] ) relative to non-responders (Supplemental Table 2 ). COVID-RIMS participants A c c e p t e d M a n u s c r i p t completed weekly (and later monthly) surveys during follow-up for a total of 10 surveys (baseline + 9 follow-up surveys); a median of 8 (IQR: 5-9) follow-up surveys were completed. CVD (18.8%) were most common. Some characteristics (male sex, Black race, comorbidity burden, exposure to more immune modulating agents) and behaviors (working onsite, in-person socialization, changes to employment related to COVID-19 or capacity to pay for disorder-associated costs) were associated with an increased odds of ever being tested for COVID-19 (Supplemental Table 3 ). Some patient characteristics were associated with social distancing behavior differences. Younger individuals, men, non-white individuals, those with lower SES, those with greater comorbidity burden and those with exposure to more immune modulating/suppressing agents were less likely to socialize in person (Supplemental Table 4 ). For example, individuals exposed to 3+ immune modulating/suppressing agents in the past year were 20% less likely to socialize in person relative to those who did not report using such medications in the past year (OR: 0.80; 95% CI: 0.65, 0.97). In contrast, individuals working on site were over two-fold more likely to report socializing in person (OR: 2.28; 95% CI: 1.96, 2.65). Results were consistent when evaluating predictors of not wearing a mask over follow-up (Supplemental Table 4 ). A c c e p t e d M a n u s c r i p t Factors associated with increased odds of contracting COVID-19 Younger age, comorbidity burden, working onsite, in-person socialization, and having a pandemicassociated change in ability to pay for disorder-associated costs were each associated with increased odds of COVID-19 in multivariable-adjusted models ( Figure 1) . Results were relatively consistent in analyses stratified by disorder (Supplemental Table 6 ). Beyond glucocorticoids, other medication classes didn't appear to be associated with COVID-19 risk. In sensitivity analyses, when we reclassified sphingosine-1-phosphate inhibitors as strong (rather than conventional) immunosuppressive agents or reclassified mycophenolate mofetil, azathioprine, or mercaptopurine as conventional (rather than strong) disease-modifying drugs (DMD), the findings were unaltered. Likewise, removing natalizumab or vedolizumab from biologic therapies (since they may not affect peripheral immune responses) also didn't alter findings. Except for prednisone use in the past year (OR: 1.67; 95% CI: 1.21, 2.30), we did not find strong evidence of higher odds of COVID-19 associated with other individual medications (Supplemental Table 7 A c c e p t e d M a n u s c r i p t Assessment of risk factors for COVID-19 were consistent when excluding individuals suspected of having, but not tested for, COVID-19 (50 individuals, leaving 215 COVID-19+ cases eligible for analyses). Results were also similar when stratifying by number of surveys completed (1 SD above the mean T-scores from PROMIS measures) were 53% more likely to report an interruption in services (OR: 1.53; 95% CI: 1.20, 1.94). Men were less likely to experience an interruption in services (OR: 0.79; 95% CI: 0.64, 0.99). Findings were generally similar when considering specific reasons for disruption to services (e.g., infusions, rehabilitative services, or mental health). Over follow-up, participants reported average anxiety and depressive symptom T-scores of 51.8 [9.5] and 49.9 [8.5] , respectively. Younger participants, men, and Black/African Americans tended to report a lower burden of anxiety and depression over time (e.g., lower T-scores), while previous selfreported previous physician-diagnosed depression was associated with substantially higher anxiety and depression symptom burden ( Table 4) . Several pandemic-associated factors were also A c c e p t e d M a n u s c r i p t associated with higher symptom levels. For example, pandemic-associated changes in ability to pay for disorder-associated costs were associated with 2.17 (1.33, 3.01) points higher anxiety and 2.45 (1.70, 3.20) points higher depressive symptom T-scores. COVID-19 related changes to employment were also associated with small increases in anxiety and depressive symptoms, though these changes may not be clinically meaningful (for anxiety: 0.73 points higher; 95% CI: 0.10, 1.35; for depression: 0.80; 95% CI: 0.25, 1.34). Over the course of follow-up, the burden of depression and anxiety symptoms changed non-linearly. Peak anxiety levels occurred in November (Figure 2 ; 2.00 points higher; 95% CI: 1.60, 2.39). Depressive symptoms peaked slightly in August (0.97 points higher; 95% CI: 0.66, 1.28), though this difference may not be clinically meaningful. Longitudinal changes in anxiety and depression were similar across different conditions and across different medication classes. Herein, we assessed risk factors for COVID-19 in a large cohort of patients with known autoimmune or inflammatory conditions in a well-phenotyped prospective registry at Johns Hopkins. Adherence to in person socialization recommendations was non-uniformly distributed. Consistent with existing evidence, individuals working onsite or socializing in-person had higher odds of contracting SARS-CoV-2 and developing COVID-19 disease. In addition, diabetes, CKD, and CVD were associated with higher COVID-19 odds. With respect to immunomodulatory/suppressive medications, any glucocorticoid use in the past year was associated with increased odds of COVID-19, but other medications classes or individual medications themselves didn't appear to be associated with COVID-19 risk. Our results were consistent in sensitivity analyses, where we varied both definitions for medication exposure and COVID-19 case definitions. Beyond COVID-19 disease, general interruptions to healthcare were common; individuals with changes in their ability to pay for disorder-associated costs as well as those who experienced a COVID-19-related change to A c c e p t e d M a n u s c r i p t employment were most vulnerable to care disruptions. Overall, these findings suggest that as the COVID-19 pandemic continues to cause considerable morbidity and mortality, people with autoimmune or inflammatory disorders may be particularly vulnerable to impacts it has on maintaining health care access. Exposure to glucocorticoids may increase odds of COVID-19, with a potential non-linear association between total glucocorticoid dose and COVID-19 risk. Glucocorticoids were among the most common medications used in this population, and many previous studies suggest a link between chronic glucocorticoid exposure and infection risk in people with autoimmune or inflammatory disorders as well worse COVID-19 outcomes in rheumatology patients. [11] [12] [13] [14] [15] While it's likely our sample size and number of COVID-19 cases precluded us from identifying the precise COVID-19 risk associated with all DMDs considered, strong risk signals were not noted for more broad classifications of many of the common DMDs herein. In the MS population, some prior studies had indicated an association between anti-CD20 therapies and risk of COVID-19; these studies did not account for social distancing behaviors, which we observed were non-uniformly distributed across patients. [1, 2, 7, 16] At the same time, the populations studied (in Europe) may have other characteristics that underlie the different outcomes. Most publications evaluating risk in other autoimmune disease evaluated risk of more severe disease rather than illness as a whole. [8, 17, 18] With the success of recent COVID-19 vaccine trials, a critical next step will be to determine if and how common immunomodulating/suppressive medications or specific medication classes (e.g., Bcell depleting therapies) affect vaccination response, as has been shown for other vaccines. [19, 20] Notably, nearly half of participants who reported receiving infusion, rehabilitative, or mental health services reported a pandemic-related disruption to care. These results set the stage for future studies in this cohort assessing the downstream consequences of these changes to disease-specific A c c e p t e d M a n u s c r i p t outcomes, especially as certain subgroups of patients (e.g., those with changes to household income) may be particularly vulnerable to these potential effects. Finally, we also note non-linear changes in the burden of depression and anxiety. The sharp decrease in the trend of symptom burden between November and December could be related to announcements of the success of large COVID-19 vaccine effectiveness trials, which occurred in this period. It is also worth noting that the burden of mental health comorbidities is generally higher in many autoimmune and inflammatory disease populations relative to the general population; [21] [22] [23] [24] [25] extended periods of social isolation may exaggerate symptoms of depression and anxiety in an already vulnerable population, an important observation for providers to remember when caring for such individuals. Our study has a number of important strengths. Our study is relatively distinct from prior studies of individuals taking immune medications, which have largely focused on risk factors for poor COVID-19 outcomes. We included a large population of nearly 5000 individuals with autoimmune or inflammatory conditions who are already followed by specialists at a large health system, and, thus, may limit some biases related to right censoring inherent to studies including only hospitalized patients. Our study was also longitudinal and included information from patients collected at 10 different time points over the course of follow-up. We also included assessments of social distancing behavior in analyses to ensure that any observed differences in medication-associated risks were not driven by differences in behavior. Lastly, surveys included information related to disruptions to care that affected a substantial proportion of participating patients. To date, most reports have focused on recommendations from providers, whereas we collected such information on the observed burden in patients, which we found to be non-uniform. A c c e p t e d M a n u s c r i p t Important limitations of our study are worth noting. First, we lacked detailed information on exact timing of COVID-19 infection, so could not incorporate this information into analyses or assess potential time-varying variables. Future studies using this cohort will restrict to the subset of cases for which timing of infection is well-delineated. We also could miss potential COVID-19 cases if participants were lost to follow-up or were not tested for COVID-19 in Maryland/District of Columbia, although follow-up was relatively complete (median 8 of 9 follow-up surveys). Further, we used self-reported medications, comorbidities, COVID-19 testing and result status. We also note that certain participant characteristics and behaviors were associated with being tested for COVID-19, which could have confounded our ability to detect certain risk factors for COVID-19. We also didn't collect detailed information on glucocorticoid exposure duration or medication dosages (beyond glucocorticoids), which could possibly lead to misclassification. We have no measure of activity of autoimmune or inflammatory conditions prior to the pandemic, which has been shown to affect COVID-19 outcomes, and it's possible glucocorticoid use is an indicator for disease activity rather than a causally associated with COVID-19 [15] . Lower SES individuals may have more limited access to biologic medications or infusions services, and glucocorticoid use could serve as a surrogate for low SES. Therefore, while we adjusted for SES using the ADI (a neighborhood-level indicator), it's also possible that participant-level contributors to SES were not accounted for and could have confounded the observed association. We also identified eligible participants using diagnostic codes, which may inaccurately identify patients. Nonetheless, we required ≥2 codes for a specific disease/condition from providers in specific specialty departments to reduce potential misclassification. Results are also derived from individuals with email addresses who receive care at Johns Hopkins and responded to our initial survey invitation and may not apply to the larger group of patients or more broadly to people with autoimmune disease. Responders were more likely to be white and have higher SES, so it's possible our results have underestimated the impact of the pandemic in vulnerable groups. Dr. Fitzgerald reports salary support (NIH/NIMH 1K01MH121582-01, National MS Society TA-1805-31136), during the conduct of the study. Dr. Fitzgerald reports receiving grant NIH/NICHD (HD101056), during the last 36 months. Dr. Mecoli reports receiving grant NIAMS K23AR075898, during the conduct of the study; Dr. Mecoli also reports grants/contracts from Bill and Melinda Gates Foundation and Jerome L Greene Foundation, during the last 36 months. Dr. Sotirchos has served on scientific advisory boards for Alexion, Viela Bio and Genetech, and has received speaker honoraria from Viela Bio and Biogen; Dr. Sotirchos also reports grants/contracts from National Institutes of Health Saidha has received consulting fees from Medical Logix for the development of CME programs in neurology and has served on scientific advisory boards for Biogen, Genzyme, Genentech Corporation, EMD Serono & Celgene. He is the PI of investigator-initiated studies funded by Genentech Corporation and Biogen Idec (Investigator initiated study grant), received support from the Race to Erase MS foundation, and was the site investigator of a trial sponsored by MedDay Pharmaceuticals (Site PI for clinical trial). He has received equity compensation/holds stock or stock options for consulting from JuneBrain LLC, a retinal imaging device developer. He is the President Elect of the International MS Visual System Consortium, and a program committee member for Americas Committee for Treatment and Research in MS, and is Editor for Multiple Sclerosis Journal -Experimental, Translational and Clinical. Dr. Chen reports receiving grant NIH / NHLBI R01 HL136681 and grants for Novartis research site for: CMK389: A subject and investigator blinded, randomized, placebo-controlled, repeat-dose, multicenter study to investigate efficacy, safety, and tolerability of CMK389 in patients with chronic pulmonary sarcoidosis. Dr. Chen also reports serving on scientific advisory board for Foundation for Sarcoidosis Research, www.stoparcoidosis.org (unpaid), all during the last 36 months. Dr. Gelber reports receiving grants as a Co-Investigator for Identifying Novel Biological Pathways for Gout by Integrating DNA Methylation and Genetics (R01 AR073178-01). Dr. Gelber reports receiving $1000 honorarium as part of CME Educational Program and $750 for serving as NIH/NIAMS DSMB Chair, all during the last 36 months. Dr. Bingham has received research grants from BMS, paid to their institution/unrelated to current work, and served as a consultant to/received consulting fees from AbbVie, BMS, Eli Lilly, Gilead, Janssen, Moderna, Pfizer, Regeneron, Sanofi. He receives royalties from UpToDate (unrelated to current work). He serves on Participation on a Data Safety Monitoring Board/Advisory Board for Moderna, unrelated to current work, all during last 36 months. Dr. Shah has research grants for clinical trials from Eicos Sciences, Inc, Medpace LLC and Kadmon Corp, in scleroderma, (unrelated to Covid-19). She receives royalties from UpToDate (unrelated to Covid-19). Dr. Mowry has grants from Biogen (Site PI of sponsored and investigator-initiated studies), is site PI for studies sponsored by Biogen and Genentech, has received free medication for a clinical trial from Teva, and receives royalties for editorial duties from UpToDate; is Steering Committee Member for MS PATHS (unpaid) for Biogen, during the last 36 months. All other authors have no potential conflicts to disclose. M a n u s c r i p t M a n u s c r i p t M a n u s c r i p t Describe any efforts to address potential sources of bias. 6-7, 8-9 Study size 10 Explain how the study size was arrived at 6-7, 9 Quantitative variables 11 Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why . Statistical methods 12a Describe all statistical methods, including those used to control for confounding [8] [9] 12b Describe any methods used to examine subgroups and interactions 8-9 12c Explain how missing data were addressed 8-9 An Italian programme for COVID-19 infection in multiple sclerosis COVID-19 in multiple sclerosis patients: susceptibility, severity risk factors and serological response Frequency of infection in patients with rheumatoid arthritis compared with controls: a population-based study Disease-modifying drugs for multiple sclerosis and infection risk: a cohort study Clinical course of COVID-19 in a series of patients with chronic arthritis treated with immunosuppressive targeted therapies Cancer, immune suppression and Coronavirus Disease-19 (COVID-19): Need to manage drug safety (French Society for Oncology Pharmacy [SFPO] guidelines) Disease modifying therapies and Covid-19 severity in Multiple Sclerosis SARS-CoV-2 infection in patients with autoimmune rheumatic diseases in northeast Italy: A cross-sectional study on 916 patients Multiple sclerosis management during the COVID-19 pandemic R: A language and environment for statistical computing Common Infections in Patients Prescribed Systemic Glucocorticoids in Primary Care: A Population-Based Cohort Study Infection Risks Among Patients With Multiple Sclerosis Treated With Fingolimod, Natalizumab, Rituximab, and Injectable Therapies Immediate and delayed impact of oral glucocorticoid therapy on risk of serious infection in older patients with rheumatoid arthritis: a nested case-control analysis What do we know about the safety of corticosteroids in rheumatoid arthritis? Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance physician-reported registry Clinical Characteristics and Outcomes in Patients With Coronavirus Disease 2019 and Multiple Sclerosis Prevalence and clinical outcomes of COVID-19 in patients with autoimmune diseases: a systematic review and meta-analysis Effect of ocrelizumab on vaccine responses in patients with multiple sclerosis: The VELOCE study Immunization responses in rheumatoid arthritis patients treated with rituximab: Results from a controlled clinical trial Prevalence of Depression in Sarcoidosis: a comparison with asthmatic and healthy controls The Influence of Depression on Quality of Life in Patients with Inflammatory Bowel Disease Cognition, depression, fatigue, and quality of life in primary Sjögren's syndrome: correlations The link between multiple sclerosis and depression The multifaceted impact of anxiety and depression on patients with rheumatoid arthritis A c c e p t e d M a n u s c r i p t A c c e p t e d M a n u s c r i p t A c c e p t e d M a n u s c r i p t DMD: disease modifying drug. Odds ratios are adjusted for age, sex, race, SES, working on site, in person socialization habits (at baseline and during follow-up), smoking status, number of comorbidities, number of autoimmune or inflammatory condition diagnoses, and current smoking status *For individuals medications included in each medication class, please refer to Supplemental Table 7 . Mean differences are adjusted for age, sex, race, SES, working on site, in person socialization, number of comorbidities, number of autoimmune or inflammatory condition diagnoses, COVID-19 infection, change in employment due to COVID-19, and changes in ability to pay for disorder-associated costs.A c c e p t e d M a n u s c r i p t A c c e p t e d M a n u s c r i p t Figure 2